live better, longer
Yes, certain osteoporosis medications are associated with a rare but serious condition called osteonecrosis of the jaw (ONJ).
The medications most commonly associated with this condition are antiresorptive drugs, including bisphosphonates such as Fosamax and Reclast, and denosumab, sold under the brand name Prolia.
However, not all osteoporosis medications carry the same jaw-related risks.
Forteo (teriparatide) and Tymlos (abaloparatide) are anabolic medications that stimulate bone formation and are not associated with the same established osteonecrosis of the jaw risk as antiresorptive medications.
The risk of ONJ with osteoporosis-dose antiresorptive medications is generally very low. For patients at high risk of fracture, the benefits of treatment often outweigh this uncommon complication.
Understanding how these drugs work, what increases your risk, and what precautions to take before dental procedures can help you make a more informed decision.
Osteonecrosis of the jaw is a condition in which an area of jawbone becomes damaged and fails to heal normally.
Medication-related osteonecrosis of the jaw, commonly called MRONJ, is associated with certain medications that affect bone remodeling.
It can develop when the jawbone is unable to repair itself properly, sometimes following dental procedures that expose or disturb bone.
Symptoms may include persistent jaw pain, exposed bone, swelling, infection, loose teeth, or a dental extraction site that does not heal as expected.
Some cases develop without a preceding dental procedure.
Although uncommon, MRONJ can be difficult to manage and may significantly affect quality of life.
This is why understanding the risks before starting certain osteoporosis medications is important.
Your bones are constantly remodeling.
Two types of cells are responsible for this process:
Healthy bone remodeling requires both processes.
The jaw is especially interesting because it experiences frequent mechanical stress from chewing, biting, and other everyday activities.
It is also exposed to a unique oral environment containing bacteria and potential sources of inflammation.
When certain medications strongly suppress bone resorption, they can alter normal remodeling and healing.
Researchers believe this may contribute to MRONJ, particularly when combined with dental infection, trauma, or invasive procedures.
However, the exact biological mechanisms are not completely understood.
The important distinction is that different osteoporosis medications influence bone remodeling in different ways.
Osteoporosis medications fall into several categories.
Some primarily reduce bone breakdown. Others stimulate bone formation.
Understanding the difference can help explain why their jaw-related safety profiles vary.
This difference matters when discussing treatment options, particularly for patients with significant dental concerns.
But drug selection should never be based on jaw risk alone.
Fracture history, bone density, overall health, and the effectiveness of each medication must also be considered.
Fosamax and Reclast belong to a group of medications called bisphosphonates.
Bisphosphonates work by inhibiting osteoclast activity.
Because osteoclasts are responsible for bone resorption, reducing their activity slows the breakdown of existing bone.
This can improve bone mineral density and reduce fracture risk.
For someone with osteoporosis, particularly someone at high fracture risk, that can be extremely valuable.
However, bone remodeling is also involved in repairing damage.
When bone resorption is strongly suppressed, healing and remodeling in certain circumstances may be affected.
The jaw appears particularly vulnerable because of its unique mechanical and microbial environment.
The risk is much lower than many people realize.
The American Dental Association reports that MRONJ prevalence among patients receiving antiresorptive treatment for osteoporosis is approximately 0.1% at the higher end of reliable estimates.
That means the overwhelming majority of patients will not develop the condition.
Risk is considerably higher with the more intensive drug regimens used in certain cancer treatments.
This distinction is important because statistics from oncology patients are sometimes discussed alongside osteoporosis treatment, even though the medication doses and patient circumstances may be very different.
Yes.
Prolia, or denosumab, is another antiresorptive osteoporosis medication associated with MRONJ.
Unlike bisphosphonates, Prolia does not remain bound to bone for years.
Instead, it works by blocking RANKL, a protein needed for the development and activity of osteoclasts.
This creates strong suppression of bone resorption.
That suppression is one reason Prolia can be effective at reducing fractures.
But it also contributes to concerns about jaw healing in susceptible patients.
This question requires special care.
Prolia should not be stopped or delayed without a coordinated medical plan.
When denosumab is discontinued, bone turnover can rebound rapidly. This may cause substantial bone loss and increase the risk of vertebral fractures, including multiple fractures.
Therefore, simply stopping Prolia before a dental procedure is not necessarily the safer option.
Your prescribing clinician and dentist or oral surgeon should coordinate treatment decisions.
For many patients, routine dental care can continue without interrupting osteoporosis medication.
Forteo and Tymlos work differently from Fosamax, Reclast, and Prolia.
Rather than primarily suppressing bone resorption, these medications stimulate bone formation.
Forteo contains teriparatide, while Tymlos contains abaloparatide.
Both act through pathways related to parathyroid hormone signaling.
These medications increase bone formation and are often considered for patients at particularly high fracture risk.
Importantly, they have not demonstrated the same established association with medication-related osteonecrosis of the jaw.
The American Dental Association distinguishes these anabolic medications from antiresorptives when discussing MRONJ risk.
That does not mean Forteo and Tymlos have no side effects.
They have their own contraindications, precautions, and potential adverse reactions.
But jaw osteonecrosis is not considered a characteristic risk in the same way it is for bisphosphonates and denosumab.
Teriparatide has also been investigated as a potential treatment for certain cases of MRONJ.
Some research suggests that stimulating bone formation may support healing in selected patients.
However, this is a specialized clinical question, and teriparatide is not an established routine treatment for every case of jaw osteonecrosis.
A patient should never start an anabolic osteoporosis medication solely to address dental healing without appropriate medical evaluation.
Evenity, or romosozumab, requires a separate conversation.
It differs from Forteo and Tymlos because it has a dual mechanism.
It stimulates bone formation while also reducing bone resorption.
Although it has anabolic properties, rare cases of osteonecrosis of the jaw have been reported with Evenity.
Therefore, it should not be grouped with Forteo and Tymlos as having the same jaw-related safety profile.
Evenity also has important cardiovascular safety considerations.
As with every osteoporosis medication, the decision comes down to the individual's fracture risk, medical history, and overall treatment strategy.
Certain dental procedures are associated with increased MRONJ risk among patients taking antiresorptive medications.
These include tooth extractions and other procedures involving the jawbone.
But the procedure itself is not the only factor.
Other risk factors include:
Having one or more risk factors does not mean someone will develop MRONJ.
It means additional planning and preventive dental care may be appropriate.
Sometimes, yes.
For patients receiving antiresorptive medications at osteoporosis doses, dental implants are not automatically contraindicated.
However, individual risk assessment is necessary.
The situation is different for patients receiving higher-dose antiresorptive treatment for cancer-related conditions.
If you are considering implants, tell your dentist or oral surgeon which osteoporosis medications you take, how long you have taken them, and whether you have received previous treatments.
Your dental team can help evaluate the risks and discuss appropriate options.
A dental evaluation is often a good idea, especially if you have known dental disease or expect to need extractions or other invasive procedures.
The goal is to identify and address problems that could complicate treatment later.
This may include treating infections, improving periodontal health, or planning necessary dental procedures.
Good oral hygiene and regular dental care are among the most practical ways to reduce MRONJ risk.
For most people receiving osteoporosis-dose medications, routine preventive dental care can continue.
Not necessarily.
This is where the conversation needs perspective.
A hip fracture, vertebral fracture, or repeated fragility fractures can have serious consequences.
Some patients are at high enough fracture risk that effective medication may be the safest available option.
The risk of MRONJ is real, but it is usually small at osteoporosis treatment doses.
For many high-risk patients, the reduction in fracture risk outweighs the possibility of this complication.
At the same time, patients deserve a complete discussion of their available options.
This includes understanding the differences between antiresorptive medications, anabolic medications, and nonpharmacologic strategies.
The goal is not to avoid every medication.
The goal is to select the right intervention for the right person.
Medication is only one part of bone health.
Even when a drug is necessary, other interventions remain important.
A comprehensive strategy should consider progressive resistance training, appropriate impact exercise, sufficient protein, calcium and vitamin D when needed, balance training, fall prevention, and treatment of underlying medical conditions.
Hormone status, digestive health, and medication-related contributors to bone loss may also deserve evaluation.
The best strategy does not assume that medication and lifestyle must compete.
Instead, it considers how each intervention contributes to stronger bones and lower fracture risk.
Risk depends on the medication, dose, duration, underlying conditions, and dental health. Higher-dose antiresorptive treatments used in cancer care generally carry substantially greater MRONJ risk than standard osteoporosis regimens.
Forteo is not associated with the same established MRONJ risk as Fosamax. However, this does not make Forteo universally safer or more appropriate. The medications have different benefits, risks, and indications.
Tymlos is not associated with the same established jaw osteonecrosis risk as bisphosphonates and denosumab. Its other risks and precautions still need to be considered.
Dental extractions may be possible, but the decision should be coordinated with your dentist and prescribing clinician. Do not stop or delay Prolia on your own.
No. Medication-related osteonecrosis of the jaw is rare among people taking Fosamax for osteoporosis.
No validated blood test reliably predicts MRONJ. In particular, CTX should not be used as a reliable predictor of jaw osteonecrosis risk before dental procedures.
Not without medical guidance. The evidence does not support routine medication interruption for every patient, and stopping certain drugs can create additional fracture risks.
Not all osteoporosis medications affect the jaw in the same way.
Fosamax, Reclast, and Prolia are associated with rare cases of medication-related osteonecrosis of the jaw.
Forteo and Tymlos stimulate bone formation and do not have the same established MRONJ association.
Evenity has both anabolic and antiresorptive effects, and rare cases of ONJ have been reported.
These differences matter.
But so does your fracture risk.
For patients who need medication, the goal should be to choose a treatment that offers meaningful protection while minimizing unnecessary risks.
And regardless of the medication you choose, protecting your dental health, understanding your treatment plan, and communicating with your care team remain essential.
If you're considering osteoporosis medication and aren't sure how to weigh the benefits and risks, education is a powerful first step.
Inside The OsteoCollective, we help members better understand osteoporosis treatments, bone turnover markers, nutrition, exercise, hormones, and long-term bone health strategies.
You can also join our free Bone Health Masterclass to learn about common mistakes people make when trying to improve bone health and the questions worth asking before making treatment decisions.
Because osteoporosis is not the end. Deciding to take action is the beginning.
This article is for educational purposes only and is not medical advice. Osteoporosis medication decisions should be made with a qualified healthcare professional who understands your fracture history, medical conditions, dental health, and treatment goals. Do not stop, delay, or change osteoporosis medication without medical supervision.
Your Blueprint for Lasting Bone Health and Longevity
.svg)
.svg)
.svg)
.svg)
Join us LIVE November 5th, 2026 at 3:00pm EST to Learn Dr. Doug's proven framework for Osteoporosis Reversal for FREE. Yes! Reversing Osteoporosis is possible and has happened for hundreds of Dr. Doug's patients.
If you have been blind-sided, feel stuck, confused, and exhausted with your diagnosis, this Masterclass is for you!
.svg)
.svg)
